Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Urinary Bladder Neoplasms 3Neoplasms 2Urothelial Bladder Cancer 1Urologic Neoplasms 1Urinary Bladder Diseases 1Recurrence 1Driving Under the Influence 1Disease Progression 1Carcinoma, Hepatocellular 1

Interventions

Nivolumab 3Cisplatin 3capivasertib 2Gemcitabine 2Carboplatin 2tivozanib 1regorafenib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1encorafenib 1durvalumab 1copanlisib 1cemiplimab 1axicabtagene ciloleucel 1avasopasem manganese 1Valproic Acid 1Thioctic Acid 1Taxes 1Receptors, Interleukin-6 1Radiotherapy 1Radiosurgery 1RNA-Seq 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Multiparametric Magnetic Resonance Imaging 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Multiparametric Magnetic Resonance Imaging × 1 year × Clear all
NCT04692675 2026-05-06

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase NA Recruiting
508 enrolled
Genitourinary

Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡